Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Price Performance

NASDAQ EDIT traded down $0.15 during midday trading on Friday, hitting $1.92. 9,432,958 shares of the company traded hands, compared to its average volume of 4,602,734. The company has a market cap of $158.08 million, a PE ratio of -0.75 and a beta of 1.94. The company's 50-day simple moving average is $1.36 and its 200-day simple moving average is $2.60. Editas Medicine has a 52 week low of $1.12 and a 52 week high of $11.58.

Analyst Ratings Changes

A number of research firms have recently weighed in on EDIT. JPMorgan Chase & Co. cut Editas Medicine from a "neutral" rating to an "underweight" rating in a research report on Monday, December 16th. Stifel Nicolaus lowered Editas Medicine from a "buy" rating to a "hold" rating and reduced their target price for the stock from $11.00 to $3.00 in a research note on Friday, December 13th. Chardan Capital restated a "neutral" rating on shares of Editas Medicine in a research note on Friday, December 13th. Royal Bank of Canada reduced their target price on Editas Medicine from $5.00 to $4.00 and set a "sector perform" rating for the company in a research note on Friday, December 13th. Finally, Wells Fargo & Company lowered Editas Medicine from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $7.00 to $4.00 in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $7.00.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.